AlphaVax

Based in Research Triangle Park, NC, AVX has developed a new generation of vaccine products for diseases that represent significant market opportunities based on its novel, proprietary vector platform technology. AlphaVax is at the forefront of a completely new class of potent biopharmaceutical products aimed to participate in this market with its viral vector technology that has the clear potential to redefine the traditional concept of vaccines. The AlphaVax proprietary viral vector gene expression system has the potential for developing a range of effective vaccines in both cancer and infectious disease. AlphaVax is focusing the commercial potential of its alphavaccine system in cancer immunotherapy. The development of immunotherapeutic treatments for cancer is a rapidly growing area in which AlphaVax will be taking a lead position in developing new treatment modalities utilizing its proprietary technology.